Skip to Main Content
Skip Nav Destination

Targeted Radiotherapy Appropriate First Therapy for Some GEP-NETs

January 22, 2024

Abstract: Radioligand therapy with [177Lu]Lu-DOTA-TATE and octreotide extends progression-free survival and improves overall response rates in patients with gastroenteropancreatic neuroendocrine tumors compared with high-dose octreotide alone. The success of this approach may provide a model for new first-line approaches in other advanced malignancies.

You do not currently have access to this content.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal